| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
6 analysts have shared their evaluations of Pacira BioSciences (NASDAQ:PCRX) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 2 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 2 | 2 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $46.67, a high estimate of $57.00, and a low estimate of $43.00. This current average has decreased by 4.76% from the previous average price target of $49.00.
The perception of Pacira BioSciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Serge Belanger | Needham | Lowers | Buy | $43.00 | $45.00 |
| Serge Belanger | Needham | Maintains | Buy | $45.00 | - |
| Hardik Parikh | JP Morgan | Announces | Overweight | $45.00 | - |
| Oren Livnat | HC Wainwright & Co. | Maintains | Buy | $57.00 | - |
| Gregory Renza | RBC Capital | Lowers | Outperform | $45.00 | $53.00 |
| Serge Belanger | Needham | Maintains | Buy | $45.00 | - |
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Pacira BioSciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Pacira BioSciences analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Pacira BioSciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.4% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Pacira BioSciences's net margin is impressive, surpassing industry averages. With a net margin of 13.72%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Pacira BioSciences's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.92%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Pacira BioSciences's ROA excels beyond industry benchmarks, reaching 1.6%. This signifies efficient management of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 0.67, Pacira BioSciences faces challenges in effectively managing its debt levels, indicating potential financial strain.
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: PCRX
